Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
The announcement follows FDA 510(k) clearance of device
Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
It is expanding the diagnostics business footprint in North East India
The plant is expected to start commercial operations from Q4FY24
Cysoni is a bionic device that paces the heart with real-time respiratory modulation
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Subscribe To Our Newsletter & Stay Updated
